May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Bevacizumab, Cetuximab Equally Effective in <em>KRAS</em> Wild-Type mCRC
June 2nd 2014Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC).
Read More
Effect of Ziv-Aflibercept in the Bevacizumab Pre-Treated Subgroup of Patients in VELOUR
June 1st 2014Paulo Marcelo Hoff, MD, PhD, FACP, discusses a trial that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months.
Read More
Panitumumab Gains FDA Approval for KRAS Wild-Type mCRC
May 24th 2014The FDA has approved panitumumab (Vectibix) in combination with chemotherapy as a frontline treatment for patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC), based on findings from two phase III clinical trials.
Read More
FDA Panel Endorses Whole-Blood CRC Screening Tool by Narrow Margin
March 28th 2014The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA’s Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test’s benefits outweigh its risks.
Read More
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of metastatic colorectal cancer.
Watch
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
February 25th 2014RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for panitumumab in mCRC, according to an analysis of phase III, second-line data, which are consistent with previously reported data in first-line mCRC.
Read More
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
February 24th 2014Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of mCRC prior to initiating treatment with anti-EGFR monoclonal antibodies
Read More
RAS Testing Before Panitumumab Use in mCRC Confirmed by Second-Line Data
January 15th 2014RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer, according to an analysis of phase III, second-line data, which are consistent with previously reported data in first-line mCRC.
Read More
Capecitabine as Effective as Infusional Chemotherapy in Rectal Cancer
January 15th 2014According to findings from a four-arm phase III NSABP R-04 trial, single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.
Read More
Expert Perspectives: Scott Kopetz, MD, PhD, on Biomarker Models in CRC
January 13th 2014The development of predictive biomarkers is widely accepted as an important milestone in the move toward personalized, or precision, medicine and the ability to identify the right drug for the right patient. JTT interviewed Kopetz about biomarker models.
Read More
Hints at Biomarkers of Clinical Benefit From the CORRECT Trial
January 3rd 2014In September 2012, the FDA approved regorafenib for treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, with an anti-EGFR therapy.
Read More
Panitumumab in Wild-Type KRAS mCRC Trial
January 2nd 2014Recent biomarker analyses of studies involving the anti-EGFR antibody panitumumab combined with chemotherapy for treatment of mCRC have advanced clinicians’ ability to prospectively identify patients who are, more or less, likely to respond to this agent.
Read More
Additional OS and PFS Benefits With Aflibercept in Post-Hoc VELOUR Analysis
December 3rd 2013A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with mCRC.
Read More
Regorafenib in the Treatment of Colorectal Cancer
September 16th 2013Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.
Read More